Showing 1 to 12 of 125 results
Lower-Cost HIV Prevention Drug to Reach Millions
A new, injectable HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 per year in over 120 low- and middle-income countries by 2027, potentially impacting millions and accelerating efforts to curb the HIV/AIDS epidemic.
Lower-Cost HIV Prevention Drug to Reach Millions
A new, injectable HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 per year in over 120 low- and middle-income countries by 2027, potentially impacting millions and accelerating efforts to curb the HIV/AIDS epidemic.
Progress
28% Bias Score
HIV Research: Progress Toward a Cure
Professor Christian Gaebler discusses the current state of HIV research, highlighting the success of antiretroviral therapies, the "U=U" principle, and the implications of rare documented cases of functional HIV cures resulting from stem cell transplants.
HIV Research: Progress Toward a Cure
Professor Christian Gaebler discusses the current state of HIV research, highlighting the success of antiretroviral therapies, the "U=U" principle, and the implications of rare documented cases of functional HIV cures resulting from stem cell transplants.
Progress
16% Bias Score
US to Invest in New HIV Prevention Drug
The U.S. will invest in lenacapavir, a new HIV prevention drug, aiming to reach 2 million people in three years, prioritizing pregnant and breastfeeding mothers in high-burden countries to prevent mother-to-child transmission.
US to Invest in New HIV Prevention Drug
The U.S. will invest in lenacapavir, a new HIV prevention drug, aiming to reach 2 million people in three years, prioritizing pregnant and breastfeeding mothers in high-burden countries to prevent mother-to-child transmission.
Progress
20% Bias Score
EU Approves New, Two-Injection HIV Prevention Treatment
The European Commission approved Gilead's new HIV prevention injection, Yeytuo, requiring only two annual injections, offering improved prevention for at-risk populations, especially in developing countries, where a deal ensures low-cost access, despite an initial high price.
EU Approves New, Two-Injection HIV Prevention Treatment
The European Commission approved Gilead's new HIV prevention injection, Yeytuo, requiring only two annual injections, offering improved prevention for at-risk populations, especially in developing countries, where a deal ensures low-cost access, despite an initial high price.
Progress
36% Bias Score
Innovative HIV Cure Approaches Show Promise in Trials
Building on the success of stem cell transplants, innovative HIV cure approaches like combination therapies (including mRNA delivery and novel antibodies) and gene therapies are showing promise in trials, particularly in children and early-diagnosed adults, offering hope for a widely accessible cure...
Innovative HIV Cure Approaches Show Promise in Trials
Building on the success of stem cell transplants, innovative HIV cure approaches like combination therapies (including mRNA delivery and novel antibodies) and gene therapies are showing promise in trials, particularly in children and early-diagnosed adults, offering hope for a widely accessible cure...
Progress
36% Bias Score
Aidsfonds Ceases Russia Operations Amidst Growing HIV Epidemic and Government Crackdown
The Russian Public Prosecutor's Office declared the Dutch Aidsfonds an undesirable organization, prompting the Aidsfonds to immediately halt its 15-year HIV/AIDS prevention program in Russia, which had the fastest-growing HIV epidemic in Eastern Europe, due to increasing government pressure and the ...
Aidsfonds Ceases Russia Operations Amidst Growing HIV Epidemic and Government Crackdown
The Russian Public Prosecutor's Office declared the Dutch Aidsfonds an undesirable organization, prompting the Aidsfonds to immediately halt its 15-year HIV/AIDS prevention program in Russia, which had the fastest-growing HIV epidemic in Eastern Europe, due to increasing government pressure and the ...
Progress
40% Bias Score
East African Lung Cancer Study Reveals Unexpected Risk Factors
A five-year study in East Africa found lung cancer is prevalent among women and non-smokers, linked to indoor air pollution, past TB infections, and impacting older farmers and peasants.
East African Lung Cancer Study Reveals Unexpected Risk Factors
A five-year study in East Africa found lung cancer is prevalent among women and non-smokers, linked to indoor air pollution, past TB infections, and impacting older farmers and peasants.
Progress
20% Bias Score
US Foreign Aid Cuts Threaten HIV Prevention Efforts in Kenya
Reduced US funding for HIV programs in Kenya jeopardizes access to crucial preventative medications like PrEP and condoms for serodiscordant couples, leaving them vulnerable to infection.
US Foreign Aid Cuts Threaten HIV Prevention Efforts in Kenya
Reduced US funding for HIV programs in Kenya jeopardizes access to crucial preventative medications like PrEP and condoms for serodiscordant couples, leaving them vulnerable to infection.
Progress
20% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved lenacapavir, a twice-yearly HIV prevention injection, showing 100% effectiveness in clinical trials; it will be launched as 'Yetto' across the EU and several other countries, addressing the rising HIV cases (24,700 new infections in 2023, a 11.8% increase) while faci...
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved lenacapavir, a twice-yearly HIV prevention injection, showing 100% effectiveness in clinical trials; it will be launched as 'Yetto' across the EU and several other countries, addressing the rising HIV cases (24,700 new infections in 2023, a 11.8% increase) while faci...
Progress
40% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
Progress
48% Bias Score
U.S. Aid Cuts Disrupt HIV Care in South Africa
The U.S. slashing of $427 million in foreign aid to South Africa has caused the closure of 12 HIV clinics, disrupting care for over 220,000 people, mostly sex workers and transgender individuals, who face discrimination in accessing public healthcare; experts warn of hundreds of thousands of new inf...
U.S. Aid Cuts Disrupt HIV Care in South Africa
The U.S. slashing of $427 million in foreign aid to South Africa has caused the closure of 12 HIV clinics, disrupting care for over 220,000 people, mostly sex workers and transgender individuals, who face discrimination in accessing public healthcare; experts warn of hundreds of thousands of new inf...
Progress
60% Bias Score
Global Access to HIV Prevention Drug Lenacapavir
Concillia, a Zambian woman with HIV, recovered after accessing treatment and support, highlighting the life-saving potential of accessible healthcare, particularly with new drugs like lenacapavir, which is now being distributed globally, alongside AI's role in accelerating drug discovery.
Global Access to HIV Prevention Drug Lenacapavir
Concillia, a Zambian woman with HIV, recovered after accessing treatment and support, highlighting the life-saving potential of accessible healthcare, particularly with new drugs like lenacapavir, which is now being distributed globally, alongside AI's role in accelerating drug discovery.
Progress
44% Bias Score
Showing 1 to 12 of 125 results